Sarepta reports preliminary Q4 net product revenue $638.2M

Financial Update: Total net product revenue of $638.2M for the fourth quarter and $1.79B for full-year 2024, exceeding full-year guidance by over $100M. Sarepta’s (SRPT) net product revenue does not include collaboration, contract manufacturing or royalty revenue. Fourth quarter and full-year 2024 net product revenue for ELEVIDYS totaled $384.2M and $820.8M, respectively. Fourth quarter and full-year 2024 net product revenue for Sarepta’s RNA-based PMOs totaled $254M and $967.2M, respectively. As of December 31, 2024, the Company had preliminary cash, cash equivalents, restricted cash and investments of approximately $1.5B. The Company reiterates 2025 full-year total net product revenue guidance of $2.9B to $3.1B. “2024 marked the most significant year to date for Sarepta and for the patients we serve. And consistent with our long track record of execution, we ended 2024 and enter 2025 with exceptionally strong performance,” said Doug Ingram, CEO. “In the fourth quarter, we grew total net product revenue by 75% year-over-year and grew ELEVIDYS by a very robust 112% over the prior sequential quarter, overachieving our guidance by more than $60M. Our 2024 total net product revenue grew some 56% over 2023. And we were pleased to see that even in the face of a strong ELEVIDYS launch, our PMO franchise continued to perform and grow year-over-year.”